Fig. 1: S protein-specific antibody profile against WT, UK, SA and RBD-specific SA triple variants. | npj Vaccines

Fig. 1: S protein-specific antibody profile against WT, UK, SA and RBD-specific SA triple variants.

From: Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore

Fig. 1

Plasma samples were collected from COVID-19 patients with SARS-CoV-2 infections (n = 57) at median 31 days post-illness onset (pio) (mild, n = 25; moderate, n = 19; severe, n = 13). a Samples were screened at 1:100 dilution for specific IgG and IgM against the different variants of full-length SARS-CoV-2 S protein expressed on the surface of HEK293T cells. IgG (b) and IgM (c) binding across the three disease severity groups. Data were shown as mean ± SD of two independent experiments. Statistical analysis was carried out on the paired samples using the Friedman test, followed by post hoc Dunn’s multiple comparison tests. P values for comparisons between the groups are shown, where * indicates P ≤ 0.05, ** indicates P ≤ 0.01, *** indicates P ≤ 0.001, and **** indicates P ≤ 0.0001.

Back to article page